Trials / Completed
CompletedNCT03005483
Gabapentin as Adjuvant for Postoperative Pain in Pediatric Orthopedic Surgery
Placebo Controlled, Randomized,Gabapentin as Adjuvant for Postoperative Pain in Pediatric Orthopedic Surgery
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Hospital Infantil Albert Sabin · Academic / Other
- Sex
- All
- Age
- 3 Months – 16 Years
- Healthy volunteers
- Accepted
Summary
This study is a clinical trial, prospective, randomized and double-blinded. Gabapentin oral 10 mg/kg was administered to reduce the pain intensity as well as the opioid consumption in children from 3 months to 16 years submitted unilateral limb surgery.
Detailed description
This study is a clinical trial, prospective, randomized and double-blinded. Gabapentin oral 10 mg/kg was administered to reduce the pain intensity as well as the opioid consumption in children from 3 months to 16 years submitted unilateral limb surgery. The children were divided into 2 groups: the gabapentin group (GG) was administered gabapentin 1 to 2 hours before procedure (N-40) and the placebo group (GP) was administered placebo 1 to 2 hours before surgery (N-44). Both groups were subjected to the same general anesthesia protocol, opioid free, and femoral and sciatic block with bupivacaine 0.125%. All patients received dipyrone and rescue analgesic used was morphine into 2/2h. The variables studied were age, gender, weight, type of surgery, hemodynamics, postoperative pain and morphine consumption .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gabapentin | Orthopedic Surgery was applied for the treatment of osseous disorders |
| OTHER | Placebo | Orthopedic Surgery was applied for the treatment of osseous disorders |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-01-01
- Completion
- 2016-05-01
- First posted
- 2016-12-29
- Last updated
- 2016-12-29
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03005483. Inclusion in this directory is not an endorsement.